NephrolithiasisNext is a comprehensive panel for patients with symptoms of nephrolithiasis and nephrocalcinosis. Given the overlap in genetic causes and variability in clinical symptoms and presentation, NephrolithiasisNext represents the most effective way of identifying at-risk individuals or confirming a diagnosis.
| Test Code | 9580 |
| Turnaround Time (TAT) | 2-4 weeks |
| Number of Genes | 30 |
We offer family variant testing for all blood relatives of patients who undergo full single gene sequencing, multigene panel testing or exome sequencing at Ambry Genetics and are found to have a pathogenic or likely pathogenic variant. Testing must be completed within 90 days of the original report date. Whenever possible, more closely related relatives should be tested before more distant relatives. If you or a family member are interested in learning more about our family testing program or when family testing may be clinically indicated, please contact us or your provider for additional information. Note that Ambry can only provide such family testing services to patients receiving medical care in the U.S or US territories.
Order NowNephrolithiasisNext includes 30 genes associated with both syndromic and non-syndromic nephrolithiasis and nephrocalcinosis, such as primary hyperoxaluria (types 1, 2, and 3), adenine phosphoribosyltransferase (APRT) deficiency, cystinuria, Dent disease, familial hypomagnesemia and hypercalciuria and nephrocalcinosis (FHHNC), distal renal tubular acidosis, and others.
Genomic deoxyribonucleic acid (gDNA) is isolated from the patient’s specimen using a standardized methodology and quantified. Sequence enrichment of the exome and adjacent intronic nucleotides is carried out by a bait-capture methodology using long biotinylated oligonucleotide probes followed by polymerase chain reaction (PCR) and Next-Generation sequencing, and the 30 genes undergo comprehensive analysis. Reportable small insertions and deletions, potentially homozygous variants, and single nucleotide variant calls not satisfying established confidence thresholds based on coverage and alternative read ratios are verified by Sanger sequencing. Gross deletion/duplication analysis is assessed for all genes using a custom pipeline based on coverage and/or breakpoint analysis from NGS data and is followed by a confirmatory orthogonal method, as needed.